An expanded offering for medical device, in vitro diagnostics, biologics and combination product manufacturers was promised after NAMSA, a US-based contract research organisation (CRO) focused on the device sector, acquired a controlling interest in fellow specialist Alquest.

No financial terms were disclosed. But Alquest, set up in Minneapolis, US 16 years ago as a clinical research organisation and regulatory consultancy specialising in medical devices, in vitro diagnostics, biologics and combination products, said its management team and consultant staff would remain intact.

Describing the Northwood, Ohio-based NAMSA as “the world’s leading medical device contract research organisation specialising in safety evaluations”, Alquest promised the two companies would “jointly work with clients to define a clear path to regulatory approval worldwide with a comprehensive array of services supporting the entire product development process”.

Both companies are financially stable “and have been for many years”, Alquest added. Moreover, both continue to grow and expand their services across a broad spectrum despite the constrained economic climate.

Alquest serves both national and international clients, including medical device players in Germany, the UK, Austria, Switzerland, Denmark, Australia, Japan and Korea. NAMSA has a network of laboratories and affiliates spanning the US, Japan, Singapore, France, Germany, the UK and Israel.